文献速递神经免疫

多发性硬化患者接受奥瑞珠单抗及其他疾病修饰治疗后的SARS-CoV-2感染细胞免疫与体液免疫:一项多族裔观察性研究

Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
PubMed 文献 · Ann Neurol · 2022-04-01

研究纳入389例18至60岁多发性硬化患者,比较不同疾病修饰治疗(DMT)对SARS-CoV-2感染后细胞免疫和体液免疫的影响。奥瑞珠单抗组抗体反应显著减弱,S1P调节剂组T细胞(IFNγ)反应降低,那他珠单抗组升高。免疫反应与COVID-19临床严重程度不相关。

要点

  • 奥瑞珠单抗组抗体反应较其他组显著减弱(p≤0.0001)。
  • S1P调节剂组T细胞(IFNγ)反应降低(p=0.03),那他珠单抗组升高(p<0.001)。
  • 免疫反应与COVID-19临床严重程度不相关;7%(9/130)住院。

核心结论

  • DMT对SARS-CoV-2感染后的体液免疫和细胞免疫反应有不同影响,免疫反应与COVID-19临床严重程度不相关。

研究设计与样本

  • 多族裔观察性研究,纳入389例18至60岁多发性硬化患者,于2021年1月6日至2021年7月21日招募。

主要发现

  • 177例(46%)有SARS-CoV-2感染的实验室证据,其中130例有症状感染,47例无症状。
  • 奥瑞珠单抗组抗体反应较其他组显著减弱(p≤0.0001)。
  • T细胞(IFNγ)反应在S1P调节剂组降低(p=0.03),在那他珠单抗组升高(p<0.001),在其他DMT组(包括奥瑞珠单抗)相似。
  • 细胞免疫与体液免疫反应在奥瑞珠单抗组(r=0.45,p=0.0002)和非奥瑞珠单抗组(r=0.64,p<0.0001)均呈中度相关。
  • 免疫反应不因种族/族裔而异;COVID-19临床病程大多非严重且在不同DMT间相似,7%(9/130)住院。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to determine the impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. METHODS: Patients with MS aged 18 to 60 years were evaluated for anti-nucleocapsid and anti-Spike receptor-binding domain (RBD) antibody with electro-chemiluminescence immunoassay; antibody responses to Spike protein, RBD, N-terminal domain with multiepitope bead-based immunoassays (MBI); live virus immunofluorescence-based microneutralization assay; T-cell responses to SARS-CoV-2 Spike using TruCulture enzyme-linked immunosorbent assay (ELISA); and IL-2 and IFNγ ELISpot assays. Assay results were compared by DMT class. Spearman correlation and multivariate analyses were performed to examine associations between immunologic responses and infection severity. RESULTS: Between January 6, 2021, and July 21, 2021, 389 patients with MS were recruited (mean age 40.3 years; 74% women; 62% non-White). Most common DMTs were ocrelizumab (OCR)-40%; natalizumab -17%, Sphingosine 1-phosphate receptor (S1P) modulators -12%; and 15% untreated. One hundred seventy-seven patients (46%) had laboratory evidence of SARS-CoV-2 infection; 130 had symptomatic infection, and 47 were asymptomatic. Antibody responses were markedly attenuated in OCR compared with other groups (p ≤0.0001). T-cell responses (IFNγ) were decreased in S1P (p = 0.03), increased in natalizumab (p <0.001), and similar in other DMTs, including OCR. Cellular and humoral responses were moderately correlated in both OCR (r = 0.45, p = 0.0002) and non-OCR (r = 0.64, p <0.0001). Immune responses did not differ by race/ethnicity. Coronavirus disease 2019 (COVID-19) clinical course was mostly non-severe and similar across DMTs; 7% (9/130) were hospitalized. INTERPRETATION: DMTs had differential effects on humoral and cellular immune responses to SARS-CoV-2 infection. Immune responses did not correlate with COVID-19 clinical severity in this relatively young and nondisabled group of patients with MS. ANN NEUROL 2022;91:782-795.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Kister I, Patskovsky Y, Curtin R, et al. Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study. Ann Neurol. 2022. PMID: 35289960. doi:10.1002/ana.26346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。